Tadimax, 42 pcs.

In the treatment of benign prostatic hyperplasia stages I and II.

Indications

In complex therapy to eliminate dysuric disorders, with benign prostatic hyperplasia of stages I and II.

Pharmacological effect

Pharmacotherapeutic group:

Special instructions

It is recommended to consult a doctor before use.

Active ingredient

Plant extracts

Composition

Active substances:

Contraindications

Hypersensitivity to the components of the drug, severe liver dysfunction.

Side Effects

Allergic reactions are possible. In 5% of cases, at the beginning of using the drug, patients may experience a burning sensation in the anus.

Recommendations for use

Tadimax is taken 2 tablets 3 times a day after meals.

Storage conditions

In a dry place, protected from light, at a temperature of 15 to 25°C

Shelf life

3 years.

Manufacturer

Danafa Pharmaceutical Joint, Vietnam